Resumen de acción BHC
Bausch Health Companies Inc. opera como empresa diversificada de especialidades farmacéuticas y dispositivos médicos en Estados Unidos y a escala internacional.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Competidores de Bausch Health Companies Inc.
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.31 |
| 52 Week High | US$11.46 |
| 52 Week Low | US$6.09 |
| Beta | 0.82 |
| 1 Month Change | -11.50% |
| 3 Month Change | -30.58% |
| 1 Year Change | -13.80% |
| 3 Year Change | -78.90% |
| 5 Year Change | -72.42% |
| Change since IPO | 1,162.00% |
Noticias y actualizaciones recientes
The Market Doesn't Like What It Sees From Bausch Health Companies Inc.'s (NYSE:BHC) Revenues Yet As Shares Tumble 25%
May 21
Why Bausch Health Stock Plunged After Posting First-Quarter 2024 Results
May 07Recent updates
The Market Doesn't Like What It Sees From Bausch Health Companies Inc.'s (NYSE:BHC) Revenues Yet As Shares Tumble 25%
May 21Why Bausch Health Stock Plunged After Posting First-Quarter 2024 Results
May 07Bausch Health: A Timely Divestiture Is The Key To An Higher Valuation
Feb 24Bausch Health: $20bn Debt Is A Mighty Elephant In The Room
Nov 30Does Bausch Health Companies (NYSE:BHC) Have A Healthy Balance Sheet?
Nov 01Bausch Health's Debt Dilemma: Strategic Decisions And Financial Metrics
Sep 24Is Bausch Health Companies (NYSE:BHC) A Risky Investment?
Jul 24Bausch + Lomb: $2.5bn M&A Deal Shows It Hasn't Learned From Parent's Mistakes
Jul 06What To Do After Bausch Health Stock Plunged By Nearly 9% Again
Jun 07Bausch Health Companies (NYSE:BHC) Has No Shortage Of Debt
Apr 18Bausch Health: A Basket Case Of A Business Only A Hedge Fund Can Bail Out
Dec 30Bausch Health acne lotion Arazlo available in Canada under public drug plans
Dec 22Bausch Health: Things To Consider Before Investing
Dec 11Bausch Health Companies (NYSE:BHC) Strong Profits May Be Masking Some Underlying Issues
Nov 10Bausch Health Companies Q3 2022 Earnings Preview
Nov 02Bausch Health: Long-Term Need To Place Stops For Protection
Sep 28Bausch Health Companies: Equity Stub Would Benefit From Ambitious Spinoff
Sep 21Bausch Health sheds 10% as FDA grants tentative approval for Xifaxan generic
Sep 08Bausch Health begin offers to exchange debt up to $4B
Aug 31Bausch Health Stock Down 11%: Now What?
Aug 09Rentabilidad de los accionistas
| BHC | US Pharmaceuticals | Mercado US | |
|---|---|---|---|
| 7D | 0.5% | 1.3% | 1.0% |
| 1Y | -13.8% | 18.2% | 21.8% |
Rentabilidad vs. Industria: Los resultados de BHC fueron inferiores a los de la industria US Pharmaceuticals, que obtuvo un rendimiento del 13.6% el año pasado.
Rentabilidad vs. Mercado: BHC obtuvo unos resultados inferiores a los del mercado US, que fueron del 25.8% el año pasado.
Volatilidad de los precios
| BHC volatility | |
|---|---|
| BHC Average Weekly Movement | 5.9% |
| Pharmaceuticals Industry Average Movement | 9.8% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in US Market | 15.6% |
| 10% least volatile stocks in US Market | 2.9% |
Precio estable de las acciones: El precio de las acciones de BHC ha sido volátil en los últimos 3 meses.
Volatilidad a lo largo del tiempo: La volatilidad semanal de BHC (6%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| n/a | 20,270 | Tom Appio | www.bauschhealth.com |
Bausch Health Companies Inc. opera como una empresa diversificada de especialidades farmacéuticas y dispositivos médicos en Estados Unidos y a escala internacional. Desarrolla, fabrica y comercializa una gama de productos principalmente en gastroenterología, hepatología, neurología, dermatología, productos farmacéuticos internacionales, productos de venta libre (OTC), dispositivos médicos estéticos y salud ocular. La empresa opera a través de cinco segmentos: Salix, Internacional, Solta Medical, Diversified y Bausch + Lomb.
Resumen de fundamentos de Bausch Health Companies Inc.
| Estadísticas fundamentales de BHC | |
|---|---|
| Capitalización bursátil | US$2.24b |
| Beneficios(TTM) | -US$455.00m |
| Ingresos (TTM) | US$8.97b |
0.3x
Ratio precio-ventas (PS)-5.1x
Ratio precio-beneficio (PE)¿Está BHC sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de BHC | |
|---|---|
| Ingresos | US$8.97b |
| Coste de los ingresos | US$2.62b |
| Beneficio bruto | US$6.35b |
| Otros gastos | US$6.80b |
| Beneficios | -US$455.00m |
Últimos beneficios comunicados
Mar 31, 2024
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -1.24 |
| Margen bruto | 70.81% |
| Margen de beneficio neto | -5.07% |
| Ratio deuda/patrimonio | -12,686.2% |
¿Cómo se ha desempeñado BHC a largo plazo?
Ver rendimiento histórico y comparativa